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Abstract
Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate cancer, is a lethal tumor that most
commonly arises in late stages of prostate adenocarcinoma (PCA) with predilection to metastasize to visceral
organs. In the current study, we explore for evidence that Aurora kinase A (AURKA) and N-myc (MYCN) gene abnor-
malities are harbingers of treatment-related NEPC (t-NEPC). We studied primary prostate tissue from 15 hormone
naïve PCAs, 51 castration-resistant prostate cancers, and 15 metastatic tumors from 72 patients at different stages
of disease progression to t-NEPC, some with multiple specimens. Histologic evaluation, immunohistochemistry,
and fluorescence in situ hybridization were performed and correlated with clinical variables. AURKA amplification
was identified in overall 65% of PCAs (hormone naïve and treated) from patients that developed t-NEPC and in 86%
of metastases. Concurrent amplification ofMYCN was present in 70% of primary PCAs, 69% of treated PCAs, and
83% of metastases. In contrast, in an unselected PCA cohort, AURKA and MYCN amplifications were identified in
only 5% of 169 cases. When metastatic t-NEPC was compared to primary PCA from the same patients, there was
100% concordance of ERG rearrangement, 100% concordance of AURKA amplification, and 60% concordance of
MYCN amplification. In tumors with mixed features, there was also 100% concordance of ERG rearrangement and
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94% concordance of AURKA andMYCN co-amplification between areas of NEPC and adenocarcinoma. AURKA and
MYCN amplifications may be prognostic and predictive biomarkers, as they are harbingers of tumors at risk of pro-
gressing to t-NEPC after hormonal therapy.
Neoplasia (2013) 15, 1–10
Introduction
The development of neuroendocrine prostate cancer (NEPC, also
referred to as anaplastic prostate cancer) is thought to drive approx-
imately 25% of the nearly 34,000 cases per year of lethal prostate
cancer in the United States [1]. However, data from autopsy studies
suggest that the incidence of NEPC may be significantly under-
estimated [2]. It is known that the amount of neuroendocrine dif-
ferentiation increases with disease progression and correlates with
patient exposure to long-term androgen deprivation therapy. Pre-
clinical studies also support transformation of prostate adenocarcinoma
(PCA) cells into neuroendocrine cells when depleted of androgen
in vitro and in xenograft models [3–7]. Therefore, with the introduc-
tion of new highly potent androgen receptor (AR)–targeted therapies
into the clinic, the incidence of treatment-related NEPC (t-NEPC)
might escalate. Patients who develop t-NEPC have an aggressive
clinical course and often develop visceral metastases, and most
survive less than 1 year [8]. Because neuroendocrine cells do not
express AR or secrete prostate-specific antigen (PSA), the PSA level
tends to be low or does not elevate in proportion to clinical progres-
sion. Elevated serum markers of neuroendocrine differentiation, such
as chromogranin A and neuron-specific enolase (NSE), may support
the diagnosis.
The prostate cancer–specific ERG gene rearrangement occurs in
approximately 50% of t-NEPC [9–11] and there is concordance
of ERG status and other molecular abnormalities between PCA
and t-NEPC foci of mixed tumors [11]; these data strongly suggest that
there is a similar cell of origin of PCA and t-NEPC. This also dis-
tinguishes t-NEPC from neuroendocrine tumors arising from other
anatomic sites and suggests that molecular studies of PCA may
provide insight into events that occur early before the development
of t-NEPC.
We recently demonstrated that the cell cycle kinase, Aurora kinase A,
and the transcription factor, N-myc, cooperate to induce neuroendo-
crine differentiation in prostate cancer [12]. Furthermore, treatment of
NEPC models with an Aurora kinase inhibitor resulted in significant
tumor shrinkage and reversal of the neuroendocrine phenotype, thereby
providing rationale for clinical evaluation of an Aurora kinase inhibitor
for patients with t-NEPC. In that study, we also showed that concur-
rent overexpression and amplification of the Aurora kinase A gene
(AURKA) and N-myc gene (MYCN ) in metastatic t-NEPC was signif-
icantly higher (40%) when compared to an unselected cohort of local-
ized PCA (5%). Interestingly, one of the patients who progressed from
PCA to t-NEPC had amplification of AURKA and MYCN in his pri-
mary hormone naïve PCA, suggesting that these molecular events occur
early in the disease [12].
In the current study, we examined the histologic spectrum of
t-NEPC and evaluated AURKA and MYCN amplifications in primary
prostate tumors and metastases from 72 patients who developed
lethal t-NEPC.
Materials and Methods
Case Selection
Pathology material from 72 patients who clinically developed NEPC
was evaluated. Clinical parameters for the diagnosis of NEPC included
rapid progression of the disease with visceral metastases in the setting of
low (≤10 ng/ml) ormodestly rising PSA and/or elevated neuroendocrine
serum markers (chromogranin A > 5× upper limit of normal, NSE >
2× upper limit of normal). All patients received androgen deprivation
therapy before disease progression toward NEPC. Cases were iden-
tified at different collaborating institutions under Institutional Review
Board (IRB)-approved protocols for the purpose of this study. The
clinical information collected for each patient included the age at diag-
nosis of PCA, clinical stage, type of primary and systemic therapy,
interval of time between initial diagnosis and castration-resistant state,
interval of time between castration-resistant prostate cancer (CRPC)
and metastatic disease including sites of metastases, and death.
For comparison purposes, an unselected cohort of 169 patients with
localized PCA who underwent radical prostatectomy (RP) at Weill
Cornell Medical Center was used. In addition, two pathology speci-
mens from patients with primary (de novo) mixed small cell carcinoma
with prostatic adenocarcinoma were assessed, and six prostatectomy
cases of hormone naïve, localized PCA with Paneth cell–like neuro-
endocrine change were included in the study as separate controls of
low-grade neuroendocrine differentiation [13].
A summary of clinical characteristics of patients included in the
study is presented in Table 1.
Pathologic Evaluation
Formalin-fixed paraffin-embedded tissue of the aforementioned
cases was available. Regarding archival material from the 72 patients
who clinically progressed to t-NEPC, different specimens were avail-
able corresponding to different stages of disease (see below). Hema-
toxylin and eosin (H&E)–stained slides from surgical resections and
biopsies were reviewed by study pathologists (J.M.M., K.P., B.D.R.,
and M.A.R.). Pathologic evaluation included Gleason score of
untreated tumors (prostate biopsy, transurethral resection, and/or
prostatectomy specimens), histologic examination of metastases and
treated prostate tumors, and pathologic tumor stage. Classification of
the spectrum of neuroendocrine tumors, both primary and meta-
static PCAs, was applied using the definitions used in lung classifi-
cation [14,15]. Briefly, tumors with neuroendocrine morphology
were small cell carcinoma (pure or combined) and large cell neuro-
endocrine carcinoma, and non–small cell carcinomas were poorly
differentiated adenocarcinomas of the prostate with or without
neuroendocrine differentiation. Poorly differentiated adenocarci-
nomas were considered to have neuroendocrine differentiation when
more than 30% of tumor cells were positive for synaptophysin or
chromogranin A.
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Archival tissue from the 72 patients who developed t-NEPC
included 11 primary hormone naïve PCA cases only (matched treated
PCA or metastasis unavailable), 1 case of hormone naïve PCA with
available tissue of treated PCA and metastases, 3 cases of hormone
naïve PCA and subsequent metastases after treatment (matched treated
PCA unavailable), 49 treated PCA only (matched hormone naïve PCA
or metastases unavailable), 1 treated PCA and subsequent metastases
(matched hormone naïve PCA unavailable), and 7 cases of metastases
only (matched hormone naïve or treated PCA unavailable) (Table 1
and Figure W1A). A total of 15 metastatic tumors from 12 patients
were interrogated. Sites of metastases included retroperitoneum (n = 1),
colon (n = 1), bladder (n = 3), brain (n = 2), pleura (n = 1), pelvic soft
tissue (n = 2), liver (n = 1), and bone (n = 4). Some patients presented
with synchronous metastases at other anatomic locations including
peritoneum, lungs, and stomach.
Overall, the assessed pathology material of these patients, some
with multiple specimens from different stages in progression toward
t-NEPC, included 15 hormone naïve clinically localized PCAs and
66 treated tumors: 51 treated PCAs and 15 metastases, the latter
being from 12 patients (see Figure W1A).
A subset of 19 neuroendocrine tumors from non-prostate origin was
also interrogated for AURKA and MYCN amplifications and included
primary small cell carcinoma of lung (n = 12) and bladder (n = 2),
metastatic small cell carcinoma of lung to cerebellum (n = 1), well-
differentiated neuroendocrine tumor (“typical carcinoid”) of bowel
(n = 1), metastatic well-differentiated neuroendocrine tumor (“typical
carcinoid”) of bowel to liver (n = 1) and lung (n = 1), and mammary
ductal carcinoma in situ with neuroendocrine differentiation (n = 1).
Fluorescence In Situ Hybridization
To assess AURKA andMYCN amplifications and PTEN status, we
used a locus-specific probe plus reference probe fluorescence in situ
hybridization (FISH) assays as previously described [12,16]. The
reference probe was located at 10q25 (BAC RP11431P18), spanning
a stable region of the chromosome. Amplification was defined as the
presence of four or more copies on average for gene-specific (AURKA
or MYCN) signals per nucleus compared to two reference signals.
ERG rearrangement was assessed using dual-color break-apart inter-
phase FISH assay as described previously [17,18]. At least 50 nuclei
were evaluated per tissue section using a fluorescence microscope
(Olympus BX51; Olympus Optical, Tokyo, Japan).
Immunohistochemistry
Immunohistochemistry (IHC) stain was performed in a subset of
44 cases using antibodies for synaptophysin (Clone SP11 from Lab
Vision/Thermo Fisher Scientific, Kalamazoo, MI) and chromogranin A
(Clone LK2H10 from Biogenex, Fremont, CA), following vendors’
specified optimal dilutions for IHC. In a subset of 15 cases (pri-
mary PCA of patients who developed t-NEPC), IHC for Aurora
kinase A was performed (ab13824 from Abcam Inc, Cambridge, MA;
1:800 dilution).
Results
Clinical Characteristics of Patients Who Progressed to t-NEPC
Full clinical information was available in 43 of 72 patients and
partial clinical information in the remaining 29 patients. The age
at diagnosis of PCA ranged from 42 to 84 years (median = 65 years).
Time interval to progression to CRPC ranged from 2 to 10 years
(median = 4 years), time on androgen deprivation therapy ranged from
1 to 11 years (median = 4 years), and overall survival after clinical
diagnosis of NEPC ranged from 8 to 14months (median = 12months).
Treatment modalities received since diagnosis of PCA encom-
passed one or more of the following: RP, radiation therapy (external
beam radiation and brachytherapy), androgen deprivation therapy
such as luteinizing hormone-releasing hormone analogs, luteinizing
hormone-releasing hormone antagonists, and anti-androgens includ-
ing MDV3100 and abiraterone, and chemotherapy protocols with
carboplatin + paclitaxel, carboplatin + etoposide, docetaxel, irinotecan,
docetaxel + radium-223 chloride.
Detailed treatment received including hormonal and chemo-
therapy in a subset of patients along with survival, pathology, and FISH
data is presented in Table W1.
The age at diagnosis of PCA in the unselected cohort of 169 pa-
tients used for comparison (RP only) ranged from 42 to 75 years
(median = 62 years).
Histopathology
Microscopic evaluation of 51 treated PCA cases and 15 metastases
demonstrated three major histologic groups: 1) pure neuroendocrine
prostate carcinoma, which included small cell carcinoma (n = 18)
and large cell neuroendocrine carcinoma (n = 1); 2) poorly differen-
tiated adenocarcinoma with (n = 21) or without (n = 8) neuro-
endocrine differentiation; 3) mixed neuroendocrine carcinoma and
adenocarcinoma (n = 18). Among the latter group of 18 cases with
mixed morphology, the neuroendocrine carcinoma component
included areas of small cell carcinoma (n = 15) and large cell neuro-
endocrine carcinoma (n = 3) (Table 2). The spectrum of NEPC,
primary and metastatic, is illustrated in Figure 1.
The prostate specimens from two patients who presented with
primary (de novo) NEPC corresponded to one case of mixed small
Table 1. Clinicopathologic Characteristics of Patients Who Developed t-NEPC and Controls.
Archival material studied from patients who developed t-NEPC (n = 72), 100%
Primary hormone naïve PCA only (n = 11), 15.3%
Primary hormone naïve PCA, treated PCA, and subsequent metastases (n = 1), 1.4%
Primary hormone naïve PCA and subsequent metastases (n = 3), 4.2%
Gleason score of localized PCA: 3+3=6 to 5+5=10
Pathologic stage of localized PCA: pT2c N0 to pT3a N1
Treated PCA only (n = 49), 68.0%
Treated PCA and subsequent metastases (n = 1), 1.4%
Metastases only* (n = 7), 9.7%
Age at diagnosis of PCA: 42 to 84 years (median = 65 years)
Time interval to progression to CRPC: 2 to 10 years (median = 4 years)
Overall survival after clinical diagnosis of NEPC: 8 to 14 months (median = 12 months)
Treatments received as monotherapy or in combination: RP, radiation therapy, androgen
deprivation therapy including MDV3100 or abiraterone, chemotherapy (carboplatin + taxol,
carboplatin + etoposide, docetaxel, irinotecan, docetaxel + radium-223 chloride) (Table W1)
Unselected cohort of patients with localized PCA who underwent RP (n = 169), 100%
Age at diagnosis of PCA: 42 to 75 years (median = 62 years)
Gleason score of localized PCA: 3+3=6 to 4+5=9
Pathologic stage of localized PCA: pT2a N0 to pT3b N0
Primary (de novo) NEPC (mixed small cell carcinoma and PCA) (n = 2), 100%
Age at diagnosis of de novo NEPC: 65 and 67 years
Pathologic stage (RP performed): pT3a N0 both cases
Localized PCA with Paneth cell–like neuroendocrine differentiation (n = 6), 100%
Age at diagnosis of PCA: 54 to 74 years (median = 65 years)
Gleason score of localized PCA: 3+3=6 to 4+5=9
Pathologic stage of localized PCA: pT2a N0 to pT3b N1
*Fifteen metastatic sites included retroperitoneum (one), colon (one), bladder (three), brain (two),
pleura (one), pelvic soft tissue (two), liver (one), and bone (four).
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cell carcinoma with areas of PCA Gleason score 5 + 4 = 9 (prostate
needle biopsies) and one case of mixed large cell neuroendocrine car-
cinoma with areas of PCA with ductal features (transurethral resec-
tion of prostate).
The Gleason scores of 15 hormone naïve PCAs (i.e., initial diag-
nosis of patients who later developed t-NEPC) ranged from 3 + 3 = 6
to 5 + 5 = 10, and their pathologic tumor stage ranged from pT2c
N0 to pT3a N1. Areas of benign prostate tissue were also identified
in these 15 specimens.
The Gleason scores of the unselected cohort of 169 cases of local-
ized PCA ranged from 3 + 3 = 6 to 4 + 5 = 9, and their pathologic
Figure 1. Morphologic spectrum of t-NEPC. (A) Small cell carcinoma of the prostate. The tumor is composed of sheets of uniform cells
with scant cytoplasm, hyperchromatic nuclei, coarse chromatin, and unapparent nucleoli. (B) Large cell neuroendocrine carcinoma of
the prostate. Tumor is composed of sheets and ribbons of cells with abundant cytoplasm, large nuclei with coarse chromatin, brisk
mitotic activity, and foci of necrosis; pseudorosettes are also apparent. (C) Metastatic poorly differentiated adenocarcinoma of the
prostate without neuroendocrine differentiation, treated (metastatic CRPC). Sheets of tumor cells with pale eosinophilic cytoplasm
and abundant mitotic figures are seen within fibroadipose tissue. (D) Poorly differentiated adenocarcinoma of the prostate with neuro-
endocrine differentiation, treated (CRPC). Note the vaguely organoid pattern of tumor cells, which have amphophilic cytoplasm and
prominent nucleoli. (E) Poorly differentiated adenocarcinoma of the prostate with focal areas of neuroendocrine differentiation, treated
(CRPC). Areas of tumor cells with neuroendocrine differentiation are interspersed and demonstrate basophilic appearance. (F) Mixed t-NEPC
and adenocarcinoma of prostate, treated (CRPC). Areas of small cell carcinoma and poorly differentiated adenocarcinoma are seen (H&E
stain, original magnification, ×200).
Table 2. ThreeHistologic Groups of Treated PCA andMetastases fromPatientsWhoDeveloped t-NEPC.
Treated PCA cases (n = 51) and metastatic sites (n = 15) examined (n = 66), 100%
1. Pure neuroendocrine carcinoma (n = 19), 28.8%
Small cell carcinoma (n = 18)
Large cell neuroendocrine carcinoma (n = 1)
2. Mixed neuroendocrine carcinoma and adenocarcinoma (n = 18), 27.2%
With areas of small cell carcinoma (n = 15)
With areas of large cell neuroendocrine carcinoma (n = 3)
3. Poorly differentiated adenocarcinoma (n = 29), 44.0%
With neuroendocrine differentiation (n = 21)
Without neuroendocrine differentiation (n = 8)
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tumor stage ranged from pT2a N0 to pT3b N0. In addition, archival
material from this control cohort also included 50 benign prostate
tissue samples.
Gleason scores of the six PCA cases with Paneth cell–like neuro-
endocrine differentiation ranged from 3 + 3 = 6 to 4 + 5 = 9 (Table 1).
FISH and IHC Results
In the group of primary hormone naïve PCA cases from patients
who clinically progressed to t-NEPC, AURKA amplification was
identified in 10 of 15 (67%) cases, seven of which (70%) also had
concurrent MYCN amplification. Protein overexpression of Aurora
kinase A was confirmed by IHC in five of such seven cases. Aurora
kinase A overexpression was seen as multifocal and scattered positive
nuclei, as illustrated in Figure W2. The presence of AURKA or
MYCN amplification was not associated with neuroendocrine marker
(synaptophysin and chromogranin A) expression in these primary
PCA cases.
Among t-NEPC cases, AURKA amplification was identified in 29
of 46 (63%) treated PCAs and in 12 of 14 (86%) metastases that
were assessable. Concurrent MYCN amplification was present in
20 of 29 treated tumors (69%) and in 10 of 12 metastases (83%)
that were evaluable (see Figure W1B ).
Figure 2. Prostate cancer with Paneth cell–like neuroendocrine differentiation harbors AURKA amplification. (A–F) Six cases of localized
prostate cancer with Paneth cell–like change were identified and used as separate controls of low-grade neuroendocrine differentiation.
On H&E stain, tumor cells with Paneth cell–like neuroendocrine differentiation are easily identified and contain distinct large eosinophilic
granules in the cytoplasm. One case (A) demonstrated AURKA and MYCN amplifications. The other five cases (B–F) harbored AURKA
amplification only (insets). ERG rearrangement, one through insertion (D) and one through deletion (A), is identified in two of these cases
(insets). Clusters of tumor cells with Paneth cell–like neuroendocrine differentiation are located around asterisks, and more focal areas
are marked with arrowheads (H&E stain, original magnification, ×400; FISH images, original magnification, ×600).
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In only two of all 75 specimens assessable by FISH did MYCN
gain occurred without concurrent AURKA amplification; both cases
previously treated with hormonal therapy, one was obtained from
prostate and the other from a bladder mass.
In contrast, AURKA amplifications were identified only in 5%
(8 of 169 cases) of the unselected PCA cohort, with concurrent
MYCN amplification identified in 7 of 169 of cases (not seen in
absence of AURKA amplification). Particularly noteworthy is the fact
that AURKA amplification was detected in all six cases of PCA with
Paneth cell–like neuroendocrine differentiation, one of them with
concurrent MYCN amplification (Figure 2).
Of the two de novo NEPC cases, one showed AURKA amplifica-
tion with concurrent MYCN polysomy, and the other one was neg-
ative for either amplification. The results of AURKA and MYCN
amplifications by FISH are summarized in Table 3.
AURKA and MYCN amplifications were detected in more than
95% of nuclei evaluated on each positive case. No AURKA or
MYCN amplification was detected in benign prostate tissue (n =
50). In all cases of primary PCA, the presence of AURKA andMYCN
amplifications was independent of other clinical prognostic features
(Gleason grade, serum PSA, and stage) including neuroendocrine
marker expression (chromogranin A and synaptophysin) by IHC.
In the five cases where metastatic t-NEPC was compared to pri-
mary PCA from the same patient, either hormone naïve or treated
PCA, there was 100% concordance (five of five matching cases) of
AURKA amplification. MYCN amplification was present in three of
five cases (60% concordance), with metastatic t-NEPC demon-
strating MYCN amplification at all times. Histologic and molecular
findings of three of these cases are illustrated in Figure 3. In prostate
tumors with mixed features, there was 94% concordance in AURKA/
MYCN amplification between areas of neuroendocrine carcinoma
and adenocarcinoma. An example of such combined histomorphol-
ogy is highlighted in Figure 4, with both areas showing AURKA and
MYCN amplifications.
Overall, ERG rearrangement was observed in 29 of 69 (42%)
assessable tumors (PCA and metastases) in the t-NEPC cohort, 10
through insertion and 19 through deletion. PTEN deletion was
observed in 14 of 49 (29%) assessable cases, eight of which were also
ERG rearranged. There was no association between AURKA/MYCN
amplification and ERG rearrangement or PTEN deletion status.
Among the five cases of metastatic t-NEPC with matching PCA
(hormone naïve or treated), four were positive for ERG rearrange-
ment in the PCA and corresponding metastases, and one was
negative for such gene rearrangement in both sites. This 100% con-
cordance of ERG rearrangement is compatible with a clonal origin of
t-NEPC, identical to those findings observed in tumors with mixed
features (Figure 4).
In neuroendocrine tumors from non-prostate origin, AURKA
amplification was detected in 10 of 11 (91%) assessable primary
small cell carcinomas of lung including the metastasis to cerebellum
and in one assessable primary small cell carcinoma of the bladder.
MYCN amplification was detected in seven of these cases (64%),
always in the presence of AURKA amplification. In contrast, AURKA/
MYCN amplifications were not seen in well-differentiated neuro-
endocrine tumor (“typical carcinoid”) of bowel and metastases or in
ductal carcinoma in situ with neuroendocrine differentiation.
Discussion
The findings of the current study suggest that a broader definition of
NEPC is desirable to capture the wide spectrum of this disease.
Although the occurrence of de novo NEPC is rare, the incidence of
NEPC that secondarily arises with disease progression and after
therapy appears common and is associated with poor clinical out-
come [19–25]. Given emerging preclinical and clinical evidence sup-
porting promotion of neuroendocrine transformation by androgen
deprivation therapies [3–7,26,27], we propose that these secondary
NEPC tumors should be termed t-NEPC. Widely under-recognized,
especially as patients with advanced stage disease are rarely biopsied
to make the diagnosis, progression toward an AR-negative neuro-
endocrine phenotype is one proposed mechanism by which tumors
acquire resistance to hormonal therapies. Thus, the landscape of
advanced prostate cancer is evolving as novel potent AR-targeted
therapies enter widespread clinical use (e.g., abiraterone acetate,
MDV3100, TAK700) and patients develop resistance, and the inci-
dence of t-NEPC will presumably escalate. Alternative mechanisms
of resistance also include up-regulation or continued activation of the
AR [28]. Recognition of resistance associated with the development
of an AR-negative t-NEPC versus an AR-activated CRPC is essential,
as this affects how patients may respond to subsequent therapies; for
instance, patients with t-NEPC would be less likely to respond to
hormonal agents and may better respond to chemotherapy or enroll-
ment in a clinical trial.
Although there are some limitations regarding clinical data pre-
sented in the current study, this retrospective cohort represents the
largest tissue collection of t-NEPC reported to date. The main pur-
pose of this study was to generate hypotheses regarding novel bio-
markers and insight into the pathogenesis of t-NEPC. This work
will be the basis for future clinical studies, including the prospective
evaluation of AURKA and MYCN in primary tumors and metastases
from patients with t-NEPC. If validated in prospective trials, these
biomarkers would be useful for clinical decision making. For this
purpose, defining the histomorphology and molecular characteriza-
tion of t-NEPC become critical steps toward understanding the spec-
trum of disease, especially as efforts are made to incorporate the latest
discoveries into the clinic, either as potential targets or in the form of
significant biomarkers, both for diagnostic and prognostic uses.
Planned clinical trials incorporating metastatic tumor biopsies for
Table 3. Results of AURKA and MYCN Amplifications by FISH.
Group Assessable Cases/Total Cases AURKA Amplification Concurrent MYCN Amplification
Hormone naïve PCA of patients who developed t-NEPC 15/15 67% (10/15) 70% (7/10)
Treated PCA (CRPC and t-NEPC) 46/51 63% (29/46) 69% (20/29)
Metastatic t-NEPC 14/15 86% (12/14) 83% (10/12)
Control cohort of patients with localized PCA 169/169 5% 100% (8/8)
Primary (de novo) NEPC 2/2 50% (1/2) 100% (1/1)
PCA with Paneth cell–like neuroendocrine differentiation 6/6 100% (6/6) 17% (1/6)
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Figure 3. AURKA and MYCN amplifications in primary prostatic adenocarcinoma predict the development of t-NEPC. (A–D) Top panel
illustrates several specimens from a patient at different stages of disease progression to t-NEPC. (A and B) Images of hormone naïve
prostate cancer with areas of Gleason score 3 + 3 = 6 (A) and 4 + 5 = 9 (B) at initial diagnosis. Concurrent AURKA (upper inset) and
MYCN (middle inset) amplifications are present in both areas. (C) Subsequent metastasis/local recurrence in the bladder demonstrates
poorly differentiated adenocarcinoma without neuroendocrine differentiation, exhibiting both AURKA and MYCN amplifications (upper
and middle insets, respectively). (D) Five years after treatment, the patient presents with metastatic large cell neuroendocrine carcinoma
in pelvic soft tissue. The tumor has organoid appearance focally forming pseudorosettes, and cells have abundant cytoplasm and prom-
inent nucleoli. The tumor has both AURKA and MYCN amplifications (upper and middle insets, respectively). Clonal origin is confirmed
by ERG rearrangement through translocation in all tumors (lower inset). (E and F) Center panel illustrates prostatectomy specimen from
a patient with initial diagnosis of PCA Gleason score 4 + 5 = 9 (E), which has concurrent AURKA and MYCN amplifications (upper and
middle insets, respectively). A liver biopsy 7 years after (F) shows metastatic small cell carcinoma, which harbors AURKA andMYCN co-
amplification as well. Clonal origin is confirmed by ERG rearrangement through deletion in both tumors (lower inset). (G and H) Lower
panel illustrates needle biopsies from a patient with initial diagnosis of (G) PCA Gleason score 3 + 4 = 7 with intraductal spread (IDC-P)
with amplification of AURKA (upper inset) but notMYCN (middle inset). Eight years after initial diagnosis and intermittent treatment, the
patient developed pancytopenia and bone lytic lesions, which biopsy demonstrates (H) metastatic small cell carcinoma (frozen tissue
artifact present), consistent with spread from known prostatic primary. In addition to AURKA amplification (upper inset), clonal origin is
confirmed by ERG rearrangement through translocation in both tumors (lower inset). The metastatic tumor demonstratesMYCN amplifica-
tion (middle inset) (H&E stain, original magnification, ×200; FISH images, original magnification, ×600).
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patients with CRPC including those patients with NEPC treated
with an Aurora kinase inhibitor will be valuable for prospective cor-
relation of pathologic findings and genomic sequencing results with
clinical features and will help further define t-NEPC.
Former studies have described the phenotypic features of meta-
static hormone-refractory PCA to bone [29] and visceral sites [30,31],
and of pure small cell carcinoma of prostate, which occurrence is rare
(less than 1% of PCA cases) [32]. Here, we highlight that most treated
prostate tumors and metastases from patients who clinically developed
NEPC, including de novo NEPC cases, are part of a morphologic
spectrum that encompasses pure neuroendocrine histology and mixed
tumors with areas of poorly differentiated adenocarcinoma. Although
the term anaplastic small cell carcinoma has also been used clinically
to describe tumor progression in patients with CRPC [33,34], the his-
tologic features of treated prostate tumors from patients who progress
to NEPC, both primary and metastatic, are heterogeneous. The
term t-NEPC may be a more useful descriptor for the clinical scenario
of patients with CRPC with rapid disease progression (visceral and/or
lytic bone metastases) and low serum PSA, especially in the setting of
potent androgen deprivation therapy.
Some molecular characteristics of CRPC (e.g., ERG, PTEN status)
have been described earlier [30,35–38]. In our series,ERG rearrangement
was observed in 42% of cases, which is at similar frequency as reported
in other cohorts. However, ERG rearrangement occurred more often
through deletion (as opposed to translocation), a finding that has been
previously associated with an aggressive behavior [37,39]. These find-
ings also support clonal origin of t-NEPC and acinar prostate cancer,
previously demonstrated by concordance of ERG rearrangement in
tumors with mixed features [9–11] and in primary PCA and metastatic
NEPC [8] (Figure 4). This has important clinical implications, as it sug-
gests that adenocarcinomas may harbor molecular lesions before the
development of t-NEPC, which is relevant toward the development
of novel biomarkers and identifying patients at high risk for progression.
We previously identified higher expression and amplification of
AURKA and MYCN in NEPC in contrast to hormone naïve PCA
[12]. In the current study, AURKA amplification was also detected
in overall 65%primary PCA frompatients that later developed t-NEPC,
with concurrent MYCN amplification in a substantial proportion of
cases. This is highly significant, especially when compared to 5% fre-
quency of AURKA andMYCN amplifications observed in an unselected
primary PCA population. Furthermore, these alterations were indepen-
dent of Gleason score, PSA level, or pathologic tumor stage at initial
diagnosis, suggesting that they add prognostic value. In the current
study, we also did not observe any correlation with Gleason score.
Importantly, AURKA and MYCN amplifications were also seen in
low-grade Gleason 3 + 3 = 6 tumors, the type of tumors that might
be considered for active surveillance. Because AURKA and MYCN
alterations arise early, other genetic changes are clearly also important
for disease progression. There was also high concordance of AURKA
andMYCN amplifications (100% and 60%, respectively) when ensuing
t-NEPC or later metastases were also interrogated (Figure 3); this sug-
gests that AURKA andMYCN alterations are acquired early and persist
during disease progression. The importance is two-fold: AURKA is
targetable (i.e., Aurora kinase A inhibitors), and AURKA and MYCN
amplifications may represent new prognostic and predictive biomarkers
because, as demonstrated in our current study, their presence identifies
patients with PCA who are at risk of progressing to t-NEPC after
androgen deprivation therapy. These patients may therefore benefit
from early intervention with an Aurora kinase A inhibitor.
Paneth cell–like change in PCA has been suggested to represent a
low-grade neuroendocrine differentiation with generally favorable
prognosis [13]. Noteworthy, all six cases of PCA with these features
harbored AURKA amplification. This particular histomorphology of
PCA may be enriched for AURKA amplification, with resultant sig-
nificant clinical implication (Figure 2). This might therefore suggest
that these tumors may not be low grade. In the prior study by Tamas
and Epstein [13], patients with PCA with Paneth cell–like neuro-
endocrine differentiation including tumors with Gleason pattern 5
had no evidence of progression with mean and median follow-ups
ranging from 42.5 to 60.5 months. These criteria were used to assign
PCA with Paneth cell–like neuroendocrine differentiation to a cate-
gory of favorable prognosis. Given the high association with AURKA
amplification and the development of t-NEPC illustrated in our
current study, future studies with longer follow-up and detailed
Figure 4. Concordance of AURKA and MYCN amplifications in tumors with mixed areas of neuroendocrine carcinoma and poorly dif-
ferentiated adenocarcinoma. Representative image of local recurrence of castration-resistant prostatic carcinoma with areas of mixed
small cell carcinoma (right) and adenocarcinoma (left). Both areas demonstrate concordance of AURKA andMYCN amplifications (upper
and middle insets, respectively). Clonal origin is supported by ERG rearrangement through translocation in both areas (lower inset) (H&E
stain, original magnification, ×200; FISH images, original magnification, ×600).
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hormonal therapy are needed. PCA with Paneth cell–like neuro-
endocrine differentiation should best be viewed for now as uncertain
clinical behavior.
AURKA and MYCN amplifications were also identified in small
cell carcinomas of non-prostate origin but not in well-differentiated
neuroendocrine tumors. This warrants further exploration for the
role of AURKA and MYCN in small cell carcinomas of other primary
sites. In addition, it demonstrates that both AURKA and MYCN
amplifications may be good markers of neuroendocrine differentia-
tion, but unlike the recurrent ETS rearrangements or SPOP muta-
tions [40] they are not PCA specific.
Finally, this study also highlights the divide between the clinical
presentation of NEPC and the pathologist’s view of NEPC. Surgical
pathologists only rarely encounter NEPC in their routine clinical
practice due in part to the rare nature of de novo small cell prostate
cancer, selection bias toward cases that are amenable to surgery and
radiation, and the near universal absence of systematic biopsies for
men with CRPC. More recently, clinical protocols are incorporating
biopsies during the treatment course of CRPC. As exposed in this
study and other recent studies that have evaluated metastatic samples,
there is a wider range of morphology than normally encountered in
hormone naïve prostate cancer. As a result, there is a significant gap
in knowledge as to how treatment alters the course of many solid
tumors but particularly prostate cancer, when hormonal or taxane-
based therapy can be administered on the basis of clinical symptoms
of bone pain, radiology images, or elevated PSA results without
first obtaining a tissue diagnosis. We anticipate that given the more
aggressive approach to obtaining biopsies on clinical trials for CRPC,
we will need to more formally address the pathologic and molecular
changes that occur as a result of targeted therapies. Therefore, we
would advocate keeping a more encompassing broad view for the
definition of NEPC until we better understand the biology and
response to treatment through emerging clinical trials with manda-
tory tissue biopsies.
In summary, t-NEPC is a clinical entity that has an array of
histologic features including pure neuroendocrine morphology (small
cell carcinoma in most cases) and mixed tumors with poorly differ-
entiated adenocarcinoma component. AURKA and MYCN amplifi-
cations occur early and are present in hormone naïve tumors from
patients who ultimately progress to t-NEPC after androgen depriva-
tion therapy (Figure 5). Therefore, AURKA and MYCN amplifica-
tions may be prognostic and predictive biomarkers, as they are
harbingers of tumors at risk of progressing to t-NEPC after hormonal
therapy and may identify patients that could potentially benefit from
Aurora kinase inhibitor therapy.
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Figure W1. Summary of prostate cancer specimens interrogated for AURKA and MYCN gene amplifications in the current study.
(A) Tumors from 72 patients at different stages of disease progression to t-NEPC were studied: 15 hormone naïve prostate cancers,
51 treated prostate cancer cases, and 15 metastases from 12 patients. Some patients had multiple specimens. (B) Results of AURKA
and MYCN gene amplifications evaluated by FISH in assessable cases of hormone naïve PCA, treated PCA, and metastases.
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Figure W2. Aurora kinase A overexpression is present in primary PCA with AURKA amplification from patients who later developed t-NEPC.
Aurora kinase A overexpression by IHC was detected in five of seven primary PCAs with AURKA gene amplification from patients who
clinically develop t-NEPC. Illustrated here are two of such cases. (A) Primary prostatic adenocarcinoma, Gleason score 4+ 3=7with AURKA
amplification (inset) from a 59-year-old patient who, 6 years after initial diagnosis, developed t-NEPC. (B) Overexpression of Aurora kinase A
is present. (C) Primary prostatic adenocarcinoma, Gleason score 5 + 4 = 9 with AURKA amplification (inset) from a 65-year-old patient who,
9 years after initial diagnosis, developed t-NEPC. (D) Overexpression of Aurora kinase A is present (H&E and IHC stains of A and B, original
magnification, ×400; H&E and IHC stains of C and D, original magnification, ×200; FISH images, original magnification, ×600).
